High-density lipoprotein lipid peroxidation as a molecular signature of the risk for developing cardiovascular disease: Results from MASHAD cohort

被引:19
作者
Samadi, Sara [1 ,2 ]
Mehramiz, Mehrane [3 ]
Kelesidis, Theodoros [4 ]
Mobarhan, Majid Ghayour [3 ]
Sahebkar, Amir Hosein [5 ]
Esmaily, Habibollah [3 ]
Moohebati, Mohsen [3 ]
Farjami, Zahra [3 ]
Ferns, Gordon A. [6 ]
Mohammadpour, Amir Hooshang [7 ,8 ]
Avan, Amir [2 ,3 ]
机构
[1] Mashhad Univ Med Sci, Fac Med, Dept Modern Sci & Technol, Mashhad, Razavi Khorasan, Iran
[2] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Razavi Khorasan, Iran
[3] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Razavi Khorasan, Iran
[4] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Dept Med, Los Angeles, CA 90095 USA
[5] Mashhad Univ Med Sci, Fac Med, Dept Med Biotechnol, Mashhad, Razavi Khorasan, Iran
[6] Brighton & Sussex Med Sch, Div Med Educ, Brighton, Sussex, England
[7] Mashhad Univ Med Sci, Inst Pharmaceut Technol, Pharmaceut Res Ctr, Mashhad, Razavi Khorasan, Iran
[8] Mashhad Univ Med Sci, Sch Pharm, Dept Clin Pharm, Mashhad, Razavi Khorasan, Iran
关键词
antioxidant; HDL function; HDLox; high-density lipoprotein; inflammation; CHOLESTEROL EFFLUX CAPACITY; CORONARY-HEART-DISEASE; OXIDIZED LIPOPROTEINS; HDL; SUBFRACTIONS; ASSAY;
D O I
10.1002/jcp.28276
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
High-density lipoprotein (HDL) function rather than level may better predict cardiovascular disease (CVD). However, the contribution of the impaired antioxidant function of HDL that is associated with increased HDL lipid peroxidation (HDLox) to the development of clinical CVD remains unclear. We have investigated the association between serum HDLox with incident CVD outcomes in Mashhad cohort. Three-hundred andthirty individuals who had a median follow-up period of 7years were recruited as part of the cohort. The primary end point was cardiovascular event, including myocardial infarction, stable angina, unstable angina, or coronary revascularization. In both univariate/multivariate analyses adjusted for traditional CVD risk factors, HDLox was an independent risk factor for CVD (odds ratio, 1.62; 95% confidence interval, 1.41-1.86; p<0.001). For every increase in HDLox by 0.1 unit, there was an increase in CVD risk by 1.62-fold. In an adjusted analysis, there was a >2.5-fold increase in cardiovascular risk in individuals with HDLox higher than cutoff point of 1.06 compared to those with lower scores, suggesting HDLox>1.06 is related to the impaired HDL oxidant function and in turn exposed to elevated risk of CVD outcomes (hazard ratio, 2.72; 95% CI, 1.88-3.94). HigherHDLox is a surrogate measure of reduced HDL antioxidant function that positively associated with cardiovascular events in a population-based cohort.
引用
收藏
页码:16168 / 16177
页数:10
相关论文
共 40 条
[1]   Dysfunctional high-density lipoprotein from HIV+ individuals promotes monocyte-derived foam cell formation in vitro [J].
Angelovich, Thomas A. ;
Hearps, Anna C. ;
Oda, Michael N. ;
Borja, Mark S. ;
Huynh, Diana ;
Homann, Stefanie ;
Jaworowski, Anthony ;
Kelesidis, Theodoros .
AIDS, 2017, 31 (17) :2331-2336
[2]   Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study [J].
Annema, Wijtske ;
Dikkers, Arne ;
de Boer, Jan Freark ;
van Greevenbroek, Marleen M. J. ;
van der Kallen, Carla J. H. ;
Schalkwijk, Casper G. ;
Stehouwer, Coen D. A. ;
Dullaart, Robin P. F. ;
Tietge, Uwe J. F. .
SCIENTIFIC REPORTS, 2016, 6
[3]  
Azarpazhooh M, 2010, INT J STROKE, V5, P207
[4]   Small, Dense High-Density Lipoprotein-3 Particles Are Enriched in Negatively Charged Phospholipids Relevance to Cellular Cholesterol Efflux, Antioxidative, Antithrombotic, Anti-Inflammatory, and Antiapoptotic Functionalities [J].
Camont, Laurent ;
Lhomme, Marie ;
Rached, Fabiana ;
Le Goff, Wilfried ;
Negre-Salvayre, Anne ;
Salvayre, Robert ;
Calzada, Catherine ;
Lagarde, Michel ;
Chapman, M. John ;
Kontush, Anatol .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2013, 33 (12) :2715-2723
[5]   Increased oxidative stress in obesity and its impact on metabolic syndrome [J].
Furukawa, S ;
Fujita, T ;
Shimabukuro, M ;
Iwaki, M ;
Yamada, Y ;
Nakajima, Y ;
Nakayama, O ;
Makishima, M ;
Matsuda, M ;
Shimomura, I .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (12) :1752-1761
[6]   Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation [J].
Ghayour-Mobarhan, Majid ;
Moohebati, Mohsen ;
Esmaily, Habibollah ;
Ebrahimi, Mahmoud ;
Parizadeh, Seyed Mohammad Reza ;
Heidari-Bakavoli, Ali Reza ;
Safarian, Mohammad ;
Mokhber, Naghmeh ;
Nematy, Mohsen ;
Saber, Hamidreza ;
Mohammadi, Maryam ;
Andalibi, Mohammad Sobhan Sheikh ;
Ferns, Gordon A. ;
Azarpazhooh, Mahmoud Reza .
INTERNATIONAL JOURNAL OF PUBLIC HEALTH, 2015, 60 (05) :561-572
[7]  
Girotti AW, 1998, J LIPID RES, V39, P1529
[8]  
GORDON DJ, 1989, NEW ENGL J MED, V321, P1311
[9]   Aging affects high-density lipoprotein composition and function [J].
Holzer, Michael ;
Trieb, Markus ;
Konya, Viktoria ;
Wadsack, Christian ;
Heinemann, Akos ;
Marsche, Gunther .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2013, 1831 (09) :1442-1448
[10]   Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial [J].
Hovingh, G. Kees ;
Kastelein, John J. P. ;
van Deventer, Sander J. H. ;
Round, Patrick ;
Ford, John ;
Saleheen, Danish ;
Rader, Daniel J. ;
Brewer, H. Bryan ;
Barter, Philip J. .
LANCET, 2015, 386 (9992) :452-460